GeoVax Labs Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 11, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File No.)
|
(IRS Employee Identification No.)
|
(Address of principal executive offices) (Zip code)
(678 ) 384-7220
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
|
|
The
|
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
|
Item 1.02
|
Termination of a Material Definitive Agreement.
|
On April 11, 2025, GeoVax, Inc. (the “Company”) received written notification from Advanced Technology International (ATI) (the “Notice”) directing the Company to stop work on all of the Company’s efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; “NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine” under the Consortium Base Agreement No. 2024-564 (the “Project Agreement”) with ATI, the Rapid Response Partnership Vehicle’s Consortium Management Firm funded by the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services.
The Notice indicated that BARDA decided to terminate the contract for convenience to the government pursuant to the terms of the Project Agreement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 14, 2025
|
GEOVAX LABS, INC.
|
|||
|
By:
|
/s/ Mark W. Reynolds
|
||
|
Mark W. Reynolds
|
|||
|
Chief Financial Officer
|
|||
2